During the last session, Eton Pharmaceuticals Inc (NASDAQ:ETON)’s traded shares were 0.52 million, with the beta value of the company hitting 1.41. At the end of the trading day, the stock’s price was $16.67, reflecting an intraday gain of 2.65% or $0.43. The 52-week high for the ETON share is $16.62, that puts it up 0.3 from that peak though still a striking 81.82% gain since the share price plummeted to a 52-week low of $3.03. The company’s market capitalization is $444.00M, and the average intraday trading volume over the past 10 days was 0.33 million shares, and the average trade volume was 250.73K shares over the past three months.
Eton Pharmaceuticals Inc (ETON) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ETON has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.0.
Eton Pharmaceuticals Inc (NASDAQ:ETON) trade information
Eton Pharmaceuticals Inc (ETON) registered a 2.65% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.65% in intraday trading to $16.67, hitting a weekly high. The stock’s 5-day price performance is 16.74%, and it has moved by 32.62% in 30 days. Based on these gigs, the overall price performance for the year is 272.93%. The short interest in Eton Pharmaceuticals Inc (NASDAQ:ETON) is 0.19 million shares and it means that shorts have 0.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $13, which implies a decrease of -28.23% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11 and $15 respectively. As a result, ETON is trading at a premium of 10.02% off the target high and 34.01% off the low.
Eton Pharmaceuticals Inc (ETON) estimates and forecasts
Statistics show that Eton Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Eton Pharmaceuticals Inc (ETON) shares have gone up 369.58% during the last six months, with a year-to-date growth rate less than the industry average at -250.00% against 16.50. In the rating firms’ projections, revenue will increase 19.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.53M as predicted by 3 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 12.39M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.31M and 7.97M respectively. In this case, analysts expect current quarter sales to grow by 43.99% and then jump by 55.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 63.71%. While earnings are projected to return -216.67% in 2025.
ETON Dividends
Eton Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Eton Pharmaceuticals Inc (NASDAQ:ETON)’s Major holders
Eton Pharmaceuticals Inc insiders own 5.39% of total outstanding shares while institutional holders control 33.36%, with the float percentage being 35.26%. OPALEYE MANAGEMENT INC. is the largest shareholder of the company, while 52.0 institutions own stock in it. As of 2024-06-30, the company held over 2.4 million shares (or 9.2963% of all shares), a total value of $7.88 million in shares.
The next largest institutional holding, with 1.03 million shares, is of VANGUARD GROUP INC’s that is approximately 3.989% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.38 million.
Also, the Mutual Funds coming in first place with the largest holdings of Eton Pharmaceuticals Inc (ETON) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 681.72 shares. This amounts to just over 2.62 percent of the company’s overall shares, with a $11.36 million market value. The same data shows that the other fund manager holds slightly less at 307.58, or about 1.18% of the stock, which is worth about $5.13 million.
